Gestational diabetes test may predict Type 2 diabetes among women
TEL AVIV, Israel A new Tel Aviv University study found a test used to diagnose gestational diabetes in women could be a key indicator to diagnosing Type 2 diabetes.
The study — led by Gabriel Chodick of Tel Aviv University’s department of epidemiology and preventive medicine at the Sackler faculty of medicine — found that women who "failed" the glucose challenge test, a series of four blood tests conducted over a single four-hour period, have a higher chance of developing adult onset diabetes later in life. Chodick and colleagues collected data on more than 185,000 women in Israel who took the glucose challenge test, then acquired information from the nation’s health registry as to what percentage of these women contracted diabetes later in life.
Chodick noted that nearly half of the women who failed all four parts of the four-part tests, demonstrating an elevated blood sugar level, developed Type 2 diabetes within 10 years. Those who failed 3-of-the-4 tests had a 20% overall chance of developing the disease within the same period. "This is the first-ever study to show the long-term health of those who failed the glucose challenge test," Chodick said.
Gestational diabetes is developed among women while they are about 28 weeks pregnant or later, when the body is not able to make and use all the insulin it needs for pregnancy.
Crucell recommends J&J bid to shareholders
NEW YORK A few weeks after Johnson & Johnson announced it would purchase the remainder of Dutch biotech firm Crucell it doesn’t already own for about $2.4 billion, J&J received backing for the bid.
Crucell recommended the offer to the shareholders but not without receiving some criticism from shareholders Delta Lloyd Asset Management, Robeco and the Van Herk Group, which said the offer from J&J "undervalued" Crucell’s worth. The fund managers jointly control at least 15.5% of Crucell, according to Reuters.
"We would not tender our shares at this price. J&J gets a lot of value from this deal, given its client base and the sales potential involved. We consider this the starting point, Crucell’s management would need to convince us in the coming days [on the price]," Jack Jonk, head of equity at Delta Lloyd Asset Management, said.
J&J said it would benefit from Crucell’s expertise in vaccines and gain a “strong platform” in the vaccine market. The drug maker said it plans to keep Crucell as the center for vaccines in the conglomerate and maintain its headquarters in Leiden, Netherlands.
Pfizer completes FoldRx acquisition
NEW YORK Pfizer on Wednesday announced the completion of its acquisition of a privately held drug discovery and clinical development company.
FoldRx now is a wholly owned subsidiary of Pfizer, Pfizer said. FoldRx’s portfolio includes clinical and preclinical programs for investigational compounds to treat diseases caused by protein misfolding, which increasingly is recognized as an underlying cause in many chronic degenerative diseases.
The acquisition was announced Sept. 1.